The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Open accessAbstract
// Amy B. Hall 1,* , Dave Newsome 1,* , Yuxin Wang 1,* , Diane M. Boucher 1 , Brenda Eustace 1 , Yong Gu 1 , Brian Hare 1 , Mac A. Johnson 1 , Howard Li 1 , Sean Milton 1 , Cheryl E. Murphy 1 , Darin Takemoto 1 , Crystal Tolman 1 , Mark Wood 1 , Peter Charlton 2 , Jean-Damien Charrier 2 , Brinley Furey 1 , Julian Golec 2 , Philip M. Reaper 2 and John R. Pollard 2 1 Vertex Pharmaceuticals Inc, Boston, MA, USA 2 Vertex Pharmaceuticals (Europe) Ltd, Milton Park, Abingdon, Oxfordshire, UK * These authors contributed equally to this work Correspondence: John R Pollard , email: // Keywords : ATR, DNA damage response, VX-970 Received : June 9, 2014 Accepted : July 2, 2014 Published : July 3, 2014 Abstract Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents. However, there are limited in vivo proof-of-concept data for ATR inhibition. To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1. VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed. In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts. The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model. These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 9×
“This has been attributed to a synthetic lethal relationship between the ATR and ATM signaling pathways[8, 14-17, 19].”
BackgroundMethodInfluentialToledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290
ATR and H2AX cooperate in maintaining genome stability under replication stress
Chanoux, R. A., Yin, B., Urtishak, K. A., Asare, A., Bassing, C. H., & Brown, E. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806739200 · Cited by 130
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17127-2 · Cited by 362
Self-citationTargeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Lecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 265
Vendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
Metadata
- Authors
- Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., Murphy, C. E., Takemoto, D., Tolman, C., Wood, M., Charlton, P., Charrier, J.-D., Furey, B., Golec, J., Reaper, P. M., & Pollard, J. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-07-03
- Volume
- 5
- Issue
- 14
- Pages
- 5674-5685
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2132089894
- Cited by
- 199
- References
- 10
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.